NasdaqCM:KOOL

Stock Analysis Report

Executive Summary

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.

Risks

  • Cesca Therapeutics is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Cesca Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.3%

NasdaqCM:KOOL

-1.6%

US Medical Equipment

-1.6%

US Market


1 Year Return

4.8%

NasdaqCM:KOOL

10.2%

US Medical Equipment

-3.0%

US Market

KOOL underperformed the Medical Equipment industry which returned 13.6% over the past year.

KOOL outperformed the Market in United States of America which returned -0% over the past year.


Share holder returns

KOOLIndustryMarket
7 Day3.3%-1.6%-1.6%
30 Day5.8%-3.5%-5.8%
90 Day20.7%7.4%0.2%
1 Year4.8%4.8%11.1%10.2%-0.8%-3.0%
3 Year-92.1%-92.1%65.1%60.0%38.0%29.1%
5 Year-98.9%-98.9%127.0%101.0%50.8%34.1%

Price Volatility Vs. Market

How volatile is Cesca Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cesca Therapeutics undervalued based on future cash flows and its price relative to the stock market?

1.28x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Cesca Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Cesca Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Cesca Therapeutics is loss making, we can't compare its value to the US Medical Equipment industry average.

Cesca Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Cesca Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Cesca Therapeutics is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Cesca Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

74.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Cesca Therapeutics's revenue is expected to grow by 18.8% yearly, however this is not considered high growth (20% yearly).

Cesca Therapeutics's earnings are expected to grow significantly at over 20% yearly.

Cesca Therapeutics's revenue growth is expected to exceed the United States of America market average.

Cesca Therapeutics's earnings growth is expected to exceed the United States of America market average.

Cesca Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Cesca Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Cesca Therapeutics performed over the past 5 years?

-16.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Cesca Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Cesca Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Cesca Therapeutics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Cesca Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Cesca Therapeutics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Cesca Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Cesca Therapeutics's financial position?


Financial Position Analysis

Cesca Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Cesca Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Cesca Therapeutics's level of debt (37%) compared to net worth is satisfactory (less than 40%).

Unable to establish if Cesca Therapeutics's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 4.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Cesca Therapeutics has less than a year of cash runway based on current free cash flow.

Cesca Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -8.1% each year.


Next Steps

Dividend

What is Cesca Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Cesca Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Cesca Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Cesca Therapeutics has not reported any payouts.

Unable to verify if Cesca Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Cesca Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Cesca Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Chris Xu (48yo)

2.8yrs

Tenure

US$653,000

Compensation

Dr. Xiaochun Xu, also known as Chris, M.B.A. Ph.D., is the Founder, Chairman and Chief Executive Officer of Boyalife Group since July 2009. Dr. Xu has been the Chairman of Board and Chief Executive Officer ...


CEO Compensation Analysis

Chris's remuneration is higher than average for companies of similar size in United States of America.

Chris's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.3yrs

Average Tenure

48yo

Average Age

The tenure for the Cesca Therapeutics management team is about average.


Board Age and Tenure

2.8yrs

Average Tenure

49yo

Average Age

The average tenure for the Cesca Therapeutics board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$6,30030 Aug 18
Joseph Thomis
EntityIndividual
Role
Member of the Board of Directors
Director
Shares3,500
Max PriceUS$1.80

Ownership Breakdown


Management Team

  • Phil Coelho (75yo)

    Chief Technology Officer

    • Tenure: 2.1yrs
    • Compensation: US$1.74m
  • Chris Xu (48yo)

    Chairman of the Board

    • Tenure: 2.8yrs
    • Compensation: US$653.00k
  • Jim Xu (48yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$376.00k
  • Jeff Cauble (46yo)

    Principal Financial & Accounting Officer

    • Tenure: 2.4yrs
    • Compensation: US$209.00k
  • Haihong Zhu

    President of ThermoGenesis

    • Tenure: 0.0yrs

Board Members

  • Russell Medford (64yo)

    Director

    • Tenure: 2.5yrs
    • Compensation: US$47.00k
  • Mark Westgate (49yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$38.50k
  • Solomon Hamburg

    Member of Clinical & Scientific Advisory Board

    • Tenure: 5.3yrs
  • Chris Xu (48yo)

    Chairman of the Board

    • Tenure: 2.8yrs
    • Compensation: US$653.00k
  • Lars Norgren

    Member of Clinical Advisory Board

    • Tenure: 3.4yrs
  • Jim Xu (48yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$376.00k
  • Jeff Thomis (73yo)

    Director

    • Tenure: 2.6yrs
    • Compensation: US$42.00k

Company Information

Cesca Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cesca Therapeutics Inc.
  • Ticker: KOOL
  • Exchange: NasdaqCM
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$7.466m
  • Shares outstanding: 2.42m
  • Website: https://www.cescatherapeutics.com

Number of Employees


Location

  • Cesca Therapeutics Inc.
  • 2711 Citrus Road
  • Rancho Cordova
  • California
  • 95742
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KOOLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 1987
THRNDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1987
THRPMUN (Boerse Muenchen)YesCommon StockDEEURJun 1987

Biography

Cesca Therapeutics Inc. develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The company  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/23 23:44
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.